2. Background
•
Type
:
Public (NASDAQ: ICUI)
•
Founded
:
1984
•
Headquarters :
San Clemente, California, United States
•
Key people
:
George "Doc" Lopez, MD, Founder and Chairman
Steven C. Riggs, Acting President and CEO
•
Products
:
disposable infusion therapy connectors and systems,
critical care monitoring products and systems,
oncology drug delivery systems
•
Revenue
:
$316 million (2012)
3. Values
•
We connect patients and caregivers through safe, life-saving, life-enhancing,
medical devices.
•
We connect innovation with empathy, empathy with technology, and
technology with care.
•
We connect answers to questions, outcomes to insights, and solutions to
problems.
•
We connect delivery and promise, care and cure.
•
We connect people to hope.
4. History
• The company was founded in 1984 by George "Doc" Lopez,
MD who developed a product known as the Click Lock to
better secure IV lines after he lost a patient due to an
accidental disconnect.
• In 2006, ICU Medical introduced its first products into the
oncology marketplace. The Chemo Clave system from ICU
Medical is a closed system transfer device (CSTD) that allows
pharmacists and nurses to safely mix and administer
hazardous drugs used to treat cancer patients without
exposing themselves to these drugs.
5. Acquisition
• ICU Medical acquired the former Abbott Laboratories Critical
Care business from Hospira in 2009.
• The acquisition allowed ICU to obtain new manufacturing
space in Salt Lake City, Utah.
6. Products
• Infusion Therapy
ICU Medical provides a line of needle free
IV connectors including the Neutron Catheter
Patency Device (above) as well as a line of
custom and stock IV sets.
7. Products
• Oncology
The Diana Hazardous Drug Compounding System is the latest
advance from ICU Medical for the safe handling of hazardous
drugs used to treat many forms of cancer.
8. Products
• Critical Care
The Safe Set Closed Blood Sampling System from ICU Medical
helps clinicians conserve blood in the operating room and
intensive care unit.
10. Growth Strategy
• Continue mass customization in all our
market
• Add more direct sales people to
capitalize on critical care acquisition,
relationship with GPO’s and other
market opportunities.
• Develop and launch new products
while attacking open markets with
proprietary products.
• Leverage distribution channels.
• Pursue accretive alliances and
acquisitions
• New market opportunities from
infection control and safe handling of
hazardous drug awareness regulation
